IGM Biosciences Inc (IGMS)

NASDAQ
78.72
+2.32(+3.04%)
  • Volume:
    31,538
  • Bid/Ask:
    77.90/79.54
  • Day's Range:
    77.20 - 80.77

IGMS Overview

Prev. Close
76.4
Day's Range
77.2-80.77
Revenue
-
Open
77.2
52 wk Range
41.41-133
EPS
-3.01
Volume
31,538
Market Cap
2.45B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
147,590
P/E Ratio
-
Beta
-
1-Year Change
41.53%
Shares Outstanding
32,025,953
Next Earnings Date
Nov 11, 2021
What is your sentiment on IGM Biosciences Inc?
or
Vote to see community's results!

IGM Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

IGM Biosciences Inc Company Profile

IGM Biosciences Inc Company Profile

Employees
131

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Read More
  • omg
    0
    • I'm sure long term prospect is great for this company when it become profitable 2022
      0
      • Future biggest
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.